Background: Preoperative portal vein embolization (PVE) is currently the standard technique used routinely to increase the size of the future remnant liver (FRL
Hepatocellular carcinoma (HCC) is the second leadingcause of cancer-related death worldwide. At firstdiagnosis, HCC is multifocal in about 35-40% of patients(1,2